WO1996023490A9 - Formulations et procedes permettant de reduire l'irritation cutanee - Google Patents
Formulations et procedes permettant de reduire l'irritation cutaneeInfo
- Publication number
- WO1996023490A9 WO1996023490A9 PCT/US1996/001289 US9601289W WO9623490A9 WO 1996023490 A9 WO1996023490 A9 WO 1996023490A9 US 9601289 W US9601289 W US 9601289W WO 9623490 A9 WO9623490 A9 WO 9623490A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- irritant
- skin
- irritation
- skin irritation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 240
- 206010040880 Skin irritation Diseases 0.000 title claims abstract description 62
- 231100000475 skin irritation Toxicity 0.000 title claims abstract description 62
- 230000036556 skin irritation Effects 0.000 title claims abstract description 62
- 230000001603 reducing Effects 0.000 title claims description 25
- 150000001413 amino acids Chemical class 0.000 claims abstract description 52
- 229920000768 polyamine Polymers 0.000 claims abstract description 43
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 25
- 239000002085 irritant Substances 0.000 claims description 131
- 210000003491 Skin Anatomy 0.000 claims description 90
- 230000003522 irritant Effects 0.000 claims description 58
- 231100000021 irritant Toxicity 0.000 claims description 58
- 230000000699 topical Effects 0.000 claims description 57
- 239000004615 ingredient Substances 0.000 claims description 48
- 239000000126 substance Substances 0.000 claims description 37
- 238000009472 formulation Methods 0.000 claims description 35
- 208000003251 Pruritus Diseases 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 230000000622 irritating Effects 0.000 claims description 25
- -1 retinoids Chemical class 0.000 claims description 25
- 239000006071 cream Substances 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 15
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 229960002885 Histidine Drugs 0.000 claims description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 11
- 229960003646 lysine Drugs 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 10
- 230000001186 cumulative Effects 0.000 claims description 10
- 230000001815 facial Effects 0.000 claims description 10
- 239000000344 soap Substances 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 9
- 229960003104 Ornithine Drugs 0.000 claims description 9
- 208000006641 Skin Disease Diseases 0.000 claims description 9
- 229960003121 arginine Drugs 0.000 claims description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims description 9
- 239000002781 deodorant agent Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 230000000475 sunscreen Effects 0.000 claims description 9
- 239000000516 sunscreening agent Substances 0.000 claims description 9
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 8
- 206010072082 Environmental exposure Diseases 0.000 claims description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 8
- ATHGHQPFGPMSJY-UHFFFAOYSA-N Spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 8
- 229940025703 Topical Product Drugs 0.000 claims description 8
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 7
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 7
- 206010013786 Dry skin Diseases 0.000 claims description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N Putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 6
- 210000004927 Skin cells Anatomy 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 230000001166 anti-perspirant Effects 0.000 claims description 6
- 239000003213 antiperspirant Substances 0.000 claims description 6
- 201000004624 dermatitis Diseases 0.000 claims description 6
- 230000037336 dry skin Effects 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000001105 regulatory Effects 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 210000001519 tissues Anatomy 0.000 claims description 6
- LKLYETYHDMXRAF-UHFFFAOYSA-N 2-octanoyloxybenzoic acid Chemical compound CCCCCCCC(=O)OC1=CC=CC=C1C(O)=O LKLYETYHDMXRAF-UHFFFAOYSA-N 0.000 claims description 5
- 208000006673 Asthma Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 210000001508 Eye Anatomy 0.000 claims description 5
- 239000007995 HEPES buffer Substances 0.000 claims description 5
- 206010022114 Injury Diseases 0.000 claims description 5
- 230000003255 anti-acne Effects 0.000 claims description 5
- 230000001850 reproductive Effects 0.000 claims description 5
- 229960004889 salicylic acid Drugs 0.000 claims description 5
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 claims description 4
- GHPVDCPCKSNJDR-UHFFFAOYSA-N 2-hydroxydecanoic acid Chemical compound CCCCCCCCC(O)C(O)=O GHPVDCPCKSNJDR-UHFFFAOYSA-N 0.000 claims description 4
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 claims description 4
- 229960000458 Allantoin Drugs 0.000 claims description 4
- 244000144927 Aloe barbadensis Species 0.000 claims description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 4
- 235000007639 Anthemis cotula Nutrition 0.000 claims description 4
- UKXSKSHDVLQNKG-UHFFFAOYSA-N Benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 claims description 4
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 4
- RGZSQWQPBWRIAQ-CABCVRRESA-N Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 4
- 241001634496 Cola nitida Species 0.000 claims description 4
- 235000015438 Cola nitida Nutrition 0.000 claims description 4
- 241000792859 Enema Species 0.000 claims description 4
- PHOQVHQSTUBQQK-SQOUGZDYSA-N Glucono δ-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 4
- 229960003681 Gluconolactone Drugs 0.000 claims description 4
- LPLVUJXQOOQHMX-MYOOOWEVSA-N Glycyrrhizic acid Natural products O=C(O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1 LPLVUJXQOOQHMX-MYOOOWEVSA-N 0.000 claims description 4
- 229940094952 Green Tea Extract Drugs 0.000 claims description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 4
- 229940069445 LICORICE EXTRACT Drugs 0.000 claims description 4
- 210000000088 Lip Anatomy 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 4
- 240000006223 Matricaria chamomilla Species 0.000 claims description 4
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 4
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 4
- 210000004400 Mucous Membrane Anatomy 0.000 claims description 4
- 229940116315 Oxalic Acid Drugs 0.000 claims description 4
- 108060006601 PRM1 Proteins 0.000 claims description 4
- 229940111630 Tea Tree Oil Drugs 0.000 claims description 4
- 229940045136 Urea Drugs 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000011399 aloe vera Nutrition 0.000 claims description 4
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 4
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 4
- 230000000903 blocking Effects 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 229960000539 carbamide Drugs 0.000 claims description 4
- 235000001544 chamomile Nutrition 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000007920 enema Substances 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 4
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 4
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 235000020688 green tea extract Nutrition 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000000077 insect repellent Substances 0.000 claims description 4
- 239000002973 irritant agent Substances 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 229940099690 malic acid Drugs 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 229960002510 mandelic acid Drugs 0.000 claims description 4
- 230000001333 moisturizer Effects 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 229940048914 protamine Drugs 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 claims description 4
- 229940063673 spermidine Drugs 0.000 claims description 4
- 229940063675 spermine Drugs 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 229940065721 systemic for obstructive airway disease Xanthines Drugs 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 229960001367 tartaric acid Drugs 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000010677 tea tree oil Substances 0.000 claims description 4
- 102000003922 Calcium Channels Human genes 0.000 claims description 3
- 108090000312 Calcium Channels Proteins 0.000 claims description 3
- YKPUWZUDDOIDPM-SOFGYWHQSA-N Capsaicin Chemical group COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 3
- 208000005679 Eczema Diseases 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 210000000214 Mouth Anatomy 0.000 claims description 3
- 229940051866 Mouthwash Drugs 0.000 claims description 3
- 210000003800 Pharynx Anatomy 0.000 claims description 3
- 239000005700 Putrescine Substances 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 229960004319 Trichloroacetic Acid Drugs 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 238000003287 bathing Methods 0.000 claims description 3
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 3
- 229960002504 capsaicin Drugs 0.000 claims description 3
- 229930003833 capsaicin Natural products 0.000 claims description 3
- 235000017663 capsaicin Nutrition 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 3
- 231100001003 eczema Toxicity 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 229950006191 gluconic acid Drugs 0.000 claims description 3
- 125000005842 heteroatoms Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 239000003595 mist Substances 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 150000002829 nitrogen Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 201000004681 psoriasis Diseases 0.000 claims description 3
- 239000006215 rectal suppository Substances 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000006216 vaginal suppository Substances 0.000 claims description 3
- 229940061720 Alpha Hydroxy Acids Drugs 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 2
- 210000004379 Membranes Anatomy 0.000 claims description 2
- 229940107700 Pyruvic Acid Drugs 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 229960001727 Tretinoin Drugs 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims description 2
- 230000000202 analgesic Effects 0.000 claims description 2
- 239000003212 astringent agent Substances 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 claims description 2
- 239000000882 contact lens solution Substances 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 230000002951 depilatory Effects 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 150000004715 keto acids Chemical class 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 235000020945 retinal Nutrition 0.000 claims description 2
- 239000011604 retinal Substances 0.000 claims description 2
- 230000002207 retinal Effects 0.000 claims description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 2
- 150000004492 retinoid derivatives Chemical group 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 230000035900 sweating Effects 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000002496 gastric Effects 0.000 claims 3
- 229940059082 Douche Drugs 0.000 claims 2
- 229940095399 Enema Drugs 0.000 claims 2
- 229940100618 Rectal Suppository Drugs 0.000 claims 2
- 210000002966 Serum Anatomy 0.000 claims 2
- 229940120293 Vaginal Suppository Drugs 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000001484 arginines Chemical class 0.000 claims 2
- 239000002981 blocking agent Substances 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 2
- 102000004257 potassium channel family Human genes 0.000 claims 2
- 108020001213 potassium channel family Proteins 0.000 claims 2
- 239000003195 sodium channel blocking agent Substances 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000001840 Dandruff Diseases 0.000 claims 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 claims 1
- 206010039083 Rhinitis Diseases 0.000 claims 1
- 239000007844 bleaching agent Substances 0.000 claims 1
- 230000002254 contraceptive Effects 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 229960003742 phenol Drugs 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 3
- 150000001412 amines Chemical class 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 75
- 150000001875 compounds Chemical class 0.000 description 51
- 235000001014 amino acid Nutrition 0.000 description 36
- 239000003981 vehicle Substances 0.000 description 28
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 230000035807 sensation Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 150000001261 hydroxy acids Chemical class 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 230000001953 sensory Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 5
- 235000009697 arginine Nutrition 0.000 description 5
- 235000014304 histidine Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002009 allergen Effects 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 3
- 150000004716 alpha keto acids Chemical class 0.000 description 3
- 230000002862 amidating Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 210000002569 neurons Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000037368 penetrate the skin Effects 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000000241 respiratory Effects 0.000 description 3
- 230000035909 sensory irritation Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 206010003557 Asthma exercise induced Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 210000003467 Cheek Anatomy 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010014190 Eczema asteatotic Diseases 0.000 description 2
- 229940079360 Enema for Constipation Drugs 0.000 description 2
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 2
- 229940012356 Eye Drops Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine zwitterion Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 230000000172 allergic Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000003444 anaesthetic Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000002561 chemical irritant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000002452 interceptive Effects 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 201000004335 respiratory allergy Diseases 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000001960 triggered Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JKXYHWKILNVPGC-RZVRUWJTSA-N (2S)-2,5-bis(azanyl)pentanoic acid Chemical compound NCCC[C@H](N)C(O)=O.NCCC[C@H](N)C(O)=O JKXYHWKILNVPGC-RZVRUWJTSA-N 0.000 description 1
- VUOPOLXTPXVVQF-UHFFFAOYSA-N 2-(2,2-dihydroxyethylamino)acetic acid;sodium Chemical compound [Na].OC(O)CNCC(O)=O VUOPOLXTPXVVQF-UHFFFAOYSA-N 0.000 description 1
- LHWZLUXODWUHLZ-UHFFFAOYSA-N 4-methyl-N-(4-methylphenyl)sulfonylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NS(=O)(=O)C1=CC=C(C)C=C1 LHWZLUXODWUHLZ-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical compound NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940035674 ANESTHETICS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 208000002029 Allergic Contact Dermatitis Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infection Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229940044199 Carnosine Drugs 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- BVHLGVCQOALMSV-NUBCRITNSA-N D-lysine hydrochloride Chemical compound Cl.NCCCC[C@@H](N)C(O)=O BVHLGVCQOALMSV-NUBCRITNSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N Glyoxalate, Glyoxylate Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 208000002287 Hemorrhoids Diseases 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 210000001847 Jaw Anatomy 0.000 description 1
- AKGWUHIOEVNNPC-LURJTMIESA-N L-Arginine ethyl ester Chemical compound CCOC(=O)[C@@H](N)CCCNC(N)=N AKGWUHIOEVNNPC-LURJTMIESA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 240000004119 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine zwitterion Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- 210000000929 Nociceptors Anatomy 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N OC(=O)[C@H](N)CCCNC(N)=N Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 206010036376 Post herpetic neuralgia Diseases 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 206010040882 Skin lesion Diseases 0.000 description 1
- 229940031439 Squalene Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 210000002438 Upper Gastrointestinal Tract Anatomy 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 210000000216 Zygoma Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000001153 anti-wrinkle Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- AXIQMEOYYYWDKF-LBPRGKRZSA-N benzyl (2S)-2-amino-3-(1H-imidazol-5-yl)propanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CNC=N1 AXIQMEOYYYWDKF-LBPRGKRZSA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine zwitterion Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000001955 cumulated Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 231100000080 dermatitis contact Toxicity 0.000 description 1
- 230000000249 desinfective Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- CZEPJJXZASVXQF-ZETCQYMHSA-N ethyl (2S)-2,6-diaminohexanoate Chemical compound CCOC(=O)[C@@H](N)CCCCN CZEPJJXZASVXQF-ZETCQYMHSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003090 exacerbative Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000000774 hypoallergenic Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- BXRMEWOQUXOLDH-LURJTMIESA-N methyl (2S)-2-amino-3-(1H-imidazol-5-yl)propanoate Chemical compound COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 description 1
- KPNBUPJZFJCCIQ-LURJTMIESA-N methyl L-lysinate Chemical compound COC(=O)[C@@H](N)CCCCN KPNBUPJZFJCCIQ-LURJTMIESA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000003867 nerve cell Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organs Anatomy 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000011360 silicone-based material Substances 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000037335 skin penetration Effects 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 200000000020 tissue injury Diseases 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Definitions
- skin Many substances are applied topically to the skin or mucous membranes of humans or animals (hereafter “skin”) in order to alter the subject's appearance, to protect the subject from the environment, or to produce a biological change in the skin or other tissue for therapeutic, preventive or cosmetic purposes.
- skin may generically be termed “topical products” and include such substances as cosmetics, over-the-counter and prescription topical drugs, and a variety of other products such as soaps and detergents.
- Topical products occur in a variety of forms, including solids, liquids, suspensions, semisolids (such as creams, gels, pastes or “sticks”), powders or finely dispersed liquids such as sprays or mists.
- topical products commonly classified as “cosmetics” include skin care products such as creams, lotions, moisturizers and “treatment cosmetics” such as exfoliants and/or skin cell renewal agents; fragrances such as perfumes and colognes, and deodorants; shaving-related products such as creams, "bracers” and aftershaves; depilatories and other hair removal products; skin cleansers, toners and astringents; pre- moistened wipes and washcloths; tanning lotions and sunscreens; bath products such as oils; eye care products such as eye lotions and makeup removers; foot care products such as powders and sprays; skin colorant and make-up products such as foundations, blushes, rouges, eye shadows and liners, lip colors and mascaras;
- topical drugs are many and varied, and include over-the-counter and/or prescription products such as antiperspirants, insect repellents, ocular drugs and eye care products, both therapeutic and non- therapeutic, including eyedrops, rewetting drops, saline solutions and contact lens solutions, sunscreens and sunburn treatments, anti-acne agents, antibiotics, topical respiratory agents, therapeutic retinoids, anti-dandruff agents, external analgesics such as capsaicin products, topical contraceptives, topical drug delivery systems, gastrointestinal agents, suppositories and enemas, hemorrhoid treatments, reproductive tract agents such as vaginal treatments, lozenges, and many other products with therapeutic or other effects, for use on skin or mucous membranes, including ocular, nasal, otic, laryngopharyngeal, and pulmonary membranes.
- over-the-counter and/or prescription products such as antiperspirants, insect repellents, ocular drugs and eye care products, both therapeutic and non
- topical products include hand, facial and body soaps and detergents and other forms of skin cleansers, as well as household detergents and many other household products such as solvents, propellants, polishes, lubricants, adhesives, waxes and others which are either applied topically or are topically exposed to the body during normal use.
- topical products contain chemicals which may produce "irritation,” including various inflammation symptoms, when applied to the skin or mucosa ("skin").
- the present invention is directed in part to compositions and methods for inhibiting the irritation associated with such topical products.
- the occurrence, frequency and nature of topical-product-induced irritation often varies from user to user.
- the severity of irritation to the susceptible user may range from subclinical to mild to severe.
- Typical symptoms of "irritation” include itching (pruritus), stinging, burning, tingling, "tightness,” erythema (redness) or edema (swelling).
- the irritation response may be due to the direct effect on the skin of certain topical product chemicals or to a response by the immune system directed toward the chemicals alone or in combination with skin components (e.g. allergic dermatitis).
- the sensation of itch is one of the most common skin problems experienced by humans and animals. Itch can be defined as a sensation which provokes the desire to scratch the site from which the sensation originates. All skin contains sensory nerves which can transmit itch or other similar sensory impulses in response to chemical irritation, environmental exposure or disease processes. Although the precise population of itch-producing nerves have not been identified, the thinnest unmyelinated nerve population, termed type C nociceptive neurons are thought to be the most important in producing the sensation. Itch: Mechanisms and Management of Pruritus. Jeffrey D. Bernhard, ed. (McGraw-Hill, Inc., San Francisco, 1994), pp. 1-22.
- the itch-producing nerves of the skin can be considered to be a "final common pathway" for the many irritating conditions which are ultimately sensed as itch, including chemical exposure, environmental exposure (such as that which produces dry, itchy skin) and disease processes such as atopic dermatitis. Many chemical substances are able to produce itch when topically applied to the skin. No matter what the ultimate cause of itch, the sensation experienced is the same and provokes the desire to scratch.
- Topical product active ingredients including chemicals that may also be classified as drugs, produce irritation when applied to the skin or mucous membranes. These include, but are not limited to, such ingredients as exfoliants and skin cell renewal agents, anti-acne drugs, antiperspirant compounds, antihistamines, anti-inflammatory agents, skin protective agents, insect repellent chemicals, sunscreens, nasal and respiratory medications in the form of mists or sprays, and many others. Where more than one chemical irritant is present, their irritating effects may be additive. Furthermore, chemical ingredients may react with one another, or in the environment of the skin, to form new chemicals which are irritating. The vehicles in which the active drug ingredients are formulated may also produce irritation in sensitive people, especially in the case of drugs such as topical corticosteroids.
- retinoids e.g. tretinoin, retinol and retinal
- carboxylic acids including ⁇ -hydroxy acids (e.g. lactic acid, glycolic acid), ⁇ -hydroxy acids (e.g.
- salicylic acid ⁇ -keto acids, acetic acid and trichloroacetic acid, l-pyrrolidone-5-carboxylic acid, capryloyl salicylic acid, ⁇ - hydroxy decanoic acid, ⁇ -hydroxy octanoic acid, gluconolactone, methoxypropyl gluconamide, oxalic acid, malic acid, tartaric acid, mandelic acid, benzylic acid, gluconic acid, benzoyl peroxide and phenol, among others, may cause the skin to become more sensitive to irritation triggered by other topically-applied chemicals such as moisturizers, sunscreens, fragrances, preservatives, surfactants (e.g.
- Exfoliants and other ingredients may also increase the skin's sensitivity to environmental conditions such as sunlight, wind, cold temperature and dry air, or to chemical agents such as allergens, or may exacerbate the irritation attributable to a pre-existing skin disease.
- environmental influences may themselves increase the skin's sensitivity to chemicals in topical products by reducing the epidermal skin's "barrier function.”
- the barrier function acts to minimize absorption or passage of potentially irritating chemicals through the outer "dead" cell layer of epidermal skin into the living skin tissue. Extremes of humidity, for example, can greatly increase irritation from topically-applied products.
- Winter itch A very common condition due to low humidity is termed "winter itch" in which the very low humidity characteri.stics of many cold climates (particularly when accompanied by indoor heating) or long exposure to refrigerated air from air conditioners in the summer produces itchy skin — especially in older people — which can exacerbate the irritating effects of topical products. Additionally, soaps, detergents, cleansing products, shaving creams, alcohol and other products which remove some of the skin's protective lipids and/or secretions may increase the skin's permeability and sensitivity to topically-applied chemicals which would otherwise not produce irritation.
- irritant materials such as antiperspirants, deodorants or sunscreens
- Exposure of the skin to high humidity environments or liquids may also increase the ability of potential irritants to penetrate the skin.
- the skin may become sensitized or inflamed due to infection, shaving abrasion, repeated or excessive washing or bathing, sun exposure, or other mechanical abrasion or injury, resulting in sensory irritation responses upon subsequent application of underarm deodorants, after-shaves or other topical products.
- many people have an inherent sensitivity or genetic predisposition to skin irritants.
- Other skin diseases and conditions such as allergic or non-allergic contact dermatitis, asthma (including exercise-induced asthma as may be precipitated by inhalation of cold or dry air), hay fever, allergic rhinitis, inflammatory bowel disease, psoriasis, eczema, candidiasis, post-herpetic neuralgia, infectious diseases manifested by, for example, sore throat or skin lesions, insect bites and the like produce inherent irritation which may be exacerbated by application of topical products or by exposure to chemical or environmental influences such as allergens, cold air, low humidity and the like. Many other individuals exhibit sensitive skin as a condition that is not related to an identifiable skin disease.
- exfoliants include ⁇ - and ⁇ -hydroxy carboxylic acids such as lactic acid, glycolic acid, salicylic acid and the like, ⁇ -keto acids such as pyruvic acid, as well as assorted compounds such as acetic acid and trichloroacetic acid, l-pyrrolidone-5- carboxylic acid, capryloyl salicylic acid, ⁇ -hydroxy decanoic acid, ⁇ -hydroxy octanoic acid, gluconolactone, methoxypropyl gluconamide, oxalic acid, malic acid, tartaric acid, mandelic acid, benzylic acid, glucpnic acid, peroxides, phenols, and skin cell renewal agents such as retinoids.
- Such products are used as exfoliants and/or cell renewal agents to reduce the occurrence or severity of skin wrinkles, particularly facial wrinkles, or as anti-acne, anti-"dry skin” or skin whitening agents.
- the present invention involves the surprising discovery that multiply-protonated organic polyamines (i.e., organic molecules containing two or more protonated amino functional groups), are effective in reducing the incidence and severity of irritation associated with topically applied skin irritants.
- a plurality (two or more) of the amino moities (which may be primary, secondary, tertiary, or quarternary amino functions) are protonated at the particular pH of the topically applied composition or product.
- the mutiply-protonated polyamines of the present invention are amino acids containing a positively-charged nitrogen-containing side chain, and derivatives of these amino acids.
- Amino acids are the chemical units from which proteins are made. "Amino acids” as a class are chemically based upon the so-called “natural” 20 amino acids, which are found in nature. They all have a primary amino function (-NH 2 ) and a carboxylic acid function (-COOH) which are joined to the same carbon atom (- ⁇ -amino acids) or to neighboring carbons (e.g., ⁇ -amino acids). Similar structures in this class include alpha-imino acids (e.g., proline). In addition, analogs and homologs of the natural amino acids (commonly referred to as "unnatural" amino acids, isomers and enantiomers) may also be synthesized. Amino acids and their analogs and homologs may be chemically modified to prepare unique amino acid structures. These modifications include those in which a chemical modification or substitution on the amino, carboxyl or side chain structures (derivatives) alters the amino acid.
- the anti-irritant activity of the compounds of the present invention is maintained even where the polyamine compound possesses, in addition to multiple centers of protonation, a negatively-charged functional group (e.g., HEPES, N-[2- hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid], a common biological buffer which contains, at pH's between about 1 and 7, two protonated amino moieties and one negatively-charged sulfonate functional group).
- HEPES N-[2- hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]
- a common biological buffer which contains, at pH's between about 1 and 7, two protonated amino moieties and one negatively-charged sulfonate functional group.
- various metal cations are effective at reducing irritation caused by topical application of skin irritants.
- the positive charge(s) on these anti-irritant compounds may reduce irritation by interacting with epidermal or mucosal nerve cells to prevent or counteract the sensation of irritation, and/or by interfering with irritation-inducing components of skin cells that are triggered by the application of the skin irritant.
- the positive charge(s) may alter the ability of skin nerve cells to depolarize or repolarize, as for example, by blocking or interfering with ion channel or pump operation or by altering the transmembranal action potential, or the positive charge(s) may interfere with the transmission of nerve impulses from one nerve cell to another.
- the positive charge(s) on the protonated polyamines may non-specifically bind to cell membranes and contribute to a charge shielding effect, which consequently, alters the ion regulatory activity of the cells.
- Amines particularly amino acids, are widely found in a variety of commercial topical products, especially cosmetics such as skin creams or emollients and hair care products. Small amounts of amino acids are added to these products because of their humectant properties, as they are believed to enhance transdermal penetration of water and other compounds.
- specific forms of some amino acids have been used in topical skin preparations for a variety of applications.
- salts of glutamic acid an amino acid containing an acidic negatively-charged side chain
- Sodium dihydroxyethylglycine has been used in formulating cleansing and disinfecting solutions which are also claimed to reduce pain and itching.
- U.S. Patent No. 4,868,213 (Farrish).
- N-acylates of amino acids and their salts, formed by butyric acid have been used to treat wrinkles of the human skin. See U.S. Patent No. 4,859,653 (Morelle et al.).
- the human skin presents a complex sensory and structural environment.
- the skin contains nerves and highly specific sensory organs that are specialized and disposed so as to differentiate the stimuli leading to such distinct sensations as heat, cold, pressure, pain, itch and the like.
- nerves in the skin are also responsive to native or foreign chemicals such as proteases, prostaglandins, complement-system molecules, allergens, mitogens and the like which may be presented due to tissue injury or environmental exposure.
- Agents which are effective to combat one source of sensory stimulus ⁇ for example, steroidal agents to treat skin inflammation ⁇ are ineffective against other sensory stimuli such as pressure, heat, or the transitory sting or itch caused by an applied skin care product.
- anesthetic agents which are effective to depress all sensory or even motor activity in a treated region are not desirable if only a single sensation ⁇ for example, a transitory sting or itch ⁇ is sought to be eliminated.
- the structural matrix of the epidermal skin affords a "barrier function" which tends to exclude or inhibit the entry of foreign material, including potentially therapeutic agents.
- the present invention provides 12 compositions and methods for reducing specific irritant effects from a variety of sources without negative effects such as caused by the use of anesthetics.
- the present invention is directed to the use of multiply-protonated organic polyamines (organic molecules containing two or more protonated amino functions), preferably, amino acids (and their derivatives) that possess a positively charged nitrogen-containing side chain, as ingredients to provide fast- acting, efficient and safe topical skin anti-irritant effects, and to formulations containing such compounds. It is one object of the present invention to provide ingredients, formulations and methods of use which can suppress skin irritation due to chemical or environmental exposure, or due to tissue inflammation, injury or other skin pathology.
- the invention is particularly useful for preventing, reducing or eliminating the potential irritation caused by topical application of products containing other irritating ingredients, including cosmetics such as, especially, hydroxy acid or other exfoliant containing products, facial peels, shaving products, sunscreen products, deodorants and other cosmetics as described above, as well as topical drug products containing irritating active ingredients or vehicles, and other products such as soaps, detergents, solvents and the like which are either applied topically or are topically exposed to the body during use.
- cosmetics such as, especially, hydroxy acid or other exfoliant containing products, facial peels, shaving products, sunscreen products, deodorants and other cosmetics as described above
- topical drug products containing irritating active ingredients or vehicles and other products such as soaps, detergents, solvents and the like which are either applied topically or are topically exposed to the body during use.
- the invention is also useful for preventing, reducing or eliminating the skin irritation caused by skin diseases or other conditions such as environmental exposure to irritating chemicals or influences such as wind, heat, cold and extremes in humidity, including the intrinsic irritation associated with these conditions as well as such irritation as may be exacerbated by the application of a topical product.
- the polyamine anti-irritants of the invention are included in a suitable topical vehicle at a concentration of about 10 to about 3000 mM, more preferably about 50 to about 2000 mM, and most preferably about 100 to about 1000 mM.
- one or more of the polyamines of the invention are combined in a topical product formulation further comprising a potentially irritating ingredient, the polyamine(s) being present in a total amount effective to reduce or eliminate irritation due to the irritant ingredient.
- a polyamine anti-irritant component of the present invention is combined in a hydroxy acid or other exfoliant preparation such that the pH of the hydroxy acid preparation is maintained in the range of pH 1-6, and more preferably, in the range of pH 2-4. It will be understood that, where the formulation employs an anhydrous vehicle, the acidity of the formulation may not be expressible in typical pH terms, but that such acidity will manifest itself upon exposure of the formulation to the skin where water is present both intracellularly and extracellularly.
- the compounds of the present invention may be combined in a formulation with other anti-irritants, such as steroidal or non- steroidal anti-inflammatory agents or other materials such as aloe vera, chamomile, ⁇ -bisabolol, Cola nitida extract, green tea extract, tea tree oil, licorice extract, allantoin, urea, caffeine or other xanthines, glycyrrhizic acid and its derivatives, or with other anti-irritant species such as those identified in co- pending U.S. Patent Application Serial Nos.
- steroidal or non- steroidal anti-inflammatory agents such as aloe vera, chamomile, ⁇ -bisabolol, Cola nitida extract, green tea extract, tea tree oil, licorice extract, allantoin, urea, caffeine or other xanthines, glycyrrhizic acid and its derivatives, or with other anti-irritant species such as those identified in
- the invention further provides methods of treating, reducing or eliminating skin irritation comprising the topical application of a formulation comprising an anti-irritant effective amount of one or more polyamines of the invention.
- the formulation may further include one or more potentially irritating components.
- the formulation may be applied separately and prior to application of another product containing a potentially irritating component, or the formulation may be applied alone in order to prevent the development of irritation or to treat a pre-existing irritation attributable to conditions such as skin disease, chemical irritant exposure or environmental exposure.
- aqueous-soluble multiply-protonated polyamines including amino acids (and derivatives thereof) having a positively-charged nitrogen- containing side chain
- Formulations containing such anti-irritant compounds are useful in suppressing a wide range of topical-product-induced irritation responses attributable to exfoliants, sunscreens, retinoids, anti-perspirants, deodorants, anti- acne and other products which contain components potentially capable of causing sensory irritation.
- the compounds of the present invention are useful for preventing or reducing the skin irritation caused by ⁇ - or ⁇ -hydroxy acids, ⁇ -keto acids and other carboxylic acids, as well as retinoids, phenols, peroxides and similar irritants found in over-the-counter topical products for home or cosmetologist use (such as l-pyrrolidone-5-carboxylic acid, capryloyl salicylic acid, ⁇ -hydroxy decanoic acid, ⁇ -hydroxy octanoic acid, gluconolactone, methoxypropyl gluconamide, oxalic acid, malic acid, tartaric acid, mandelic acid, benzylic acid, and gluconic acid), as well as in certain prescription topical drugs containing high (for example, 12% w/w or even higher) dosage forms of such irritants.
- formulations of the invention can also be inhibited by the formulations of the invention.
- formulations containing such compounds are useful in ameliorating irritation in conditions where the skin is inherently hypersensitive to topical products (e.g. dry skin, "winter itch,” and other inflammation or injury conditions) and in ameliorating the irritation due to such conditions even in the absence of other applied topical products.
- the formulations are also useful in treating non-human animal skin irritation, as for example dog or cat irritation and resultant scratching due to fleas or other skin disease or condition.
- An additional benefit of the present anti-irritant compounds and formulations is that they do not have the undesirable anesthetic side-effects exhibited by lidocaine and other similar skin local anesthetics.
- subjects Upon application of a solution of the compound used in the clinical trials described here, subjects typically reported no sensations other than those sensations caused by the vehicle alone, and no lack of normal sensation(s).
- the protonated polyamines of the present invention include straight-chain and branched-chain polyamines, as well as heterocyclic amines.
- the protonated amino moieties of these polyamine molecules may be primary, secondary, tertiary, or quarternary amino functions.
- the polyamine anti-irritant compounds are preferably selected from the group consisting of spermine, spermidine, putrescine, protamine, HEPES, imidazole, and piperazine, since these polyamines possess two or more protonated amino groups under acidic conditions (low pH).
- polyamines of the present invention are amino acids
- they are preferably selected from the group consisting of arginine, lysine, histidine, and ornithine, since these amino acids have, in addition to a positively-charged N- ⁇ amino moiety, a positively-charged side chain amino function at physiological pH and below.
- Arginine, lysine, histidine, and ornithine possess predominantly two positive charges at low pH (pH ⁇ 5), one positive charge on the side chain amine group and another positive charge on the N- ⁇ terminus of the amino acid backbone. It is believed that the multiply-protonated state of these amino acids at low pH contributes to these compounds' anti-irritant properties.
- substituted or otherwise derivatized forms of such amino acids are also within the scope of the present invention.
- derivatized amino acids also include analog forms of the amino acids.
- Preferred substituents include substituents (at either or both of the N- ⁇ - terminus and the C-terminus ends of the amino acid) at the N- ⁇ -terminus of the amino acid of the form RCO- or R-, carboxyl (C)-terminal substituents of the form -NH 2 , -NHNH 2 , and -NHR, where each R is independently an unsubstituted or substituted alkyl, alkenyl or alkynyl (either unbranched or branched, and preferably from 1 to about 10 carbons), or aryl, alkaryl, aralkyl or cycloalkyl (preferably of from about 3 to 20 carbons), or, in the case of -NR 2 , the R- groups are together a cyclized group forming (in attachment with the
- An amino-terminal acetyl substituent is a particularly preferred substituent for the derivatized amino acid compounds.
- Amidating or esterifying carboxyl- terminal substituents formed from unsubstituted or lower alkyl-substituted amino, or from lower alkoxy or single-ring aryloxy, groups are preferred, and groups of the form -NH 2 , -OCH 3 , -OCH 2 CH 3 are especially preferred.
- Amidating substituents are particularly preferred. Where an amidating group of the structure -NR 2 is to be cyclic in form, the N-morpholino heterocyclic structure is preferred.
- both D- and L- forms of the amino acid anti- irritant compounds of the present invention exhibit irritant reducing activity. It is expected that guanidinium, a triamine side chain constituent of arginine, may also be effective at reducing irritation. Similarly, other isomeric forms, homologs and suitable salts of the amino acid compounds are predicted to be active.
- the anti-irritant topical formulations of the invention comprise a topical vehicle suitable for administration to the animal (particularly human) skin, and an amount of one or more polyamine anti-irritant compounds of the invention effective 18 to reduce, inhibit or eliminate existing or potential skin irritation or inflammation.
- the anti-irritant topical formulations additionally contain an irritant ingredient(s) that is itself capable of inducing skin irritation, such as symptoms associated with inflammation, as, for example, a cosmetic or skin care product ingredient, or a pharmaceutically active ingredient or drug ingredient.
- an irritant ingredient(s) that is itself capable of inducing skin irritation, such as symptoms associated with inflammation, as, for example, a cosmetic or skin care product ingredient, or a pharmaceutically active ingredient or drug ingredient.
- the polyamine anti-irritant compounds for use in the anti-irritant formulations of the invention are contained in a topical formulation in a concentration effective to prevent or reduce (hereafter, "inhibit") the skin irritation and/or inflammation (such as inflammation) symptoms that are sought to be eliminated.
- the formulation preferably contains the selected compound in a suitable topical vehicle at a total concentration of about 10 to about 3000 mM, more preferably about 50 to about 2000 mM, and most preferably about 100 to about 1000 mM.
- the appropriate concentration can be achieved using a single polyamine anti- irritant component of the invention, or multiple different such compounds may be combined to yield the total desired concentration. If other anti-irritant components are included in the formulation, then lower concentrations of the compounds of the invention may be utilized.
- Preferred concentrations can also be expressed in weight/volume or weight/weight percentage terms which will vary somewhat depending on the density of the vehicle and other components in the formulation.
- the vehicle has a density of 0.93 g/ml (as in a 50:50 [by volume] mixture of 95% ethyl alcohol and water) and the nitrogenous compound is incorporated in the form of histidine (formula weight 155)
- representative molarity concentration values correspond approximately to 100 mM: 0.78% (w/v) 0.83% (w/w)
- compositions are readily formulated and do not leave any significant visible residue when applied to the skin.
- Higher concentration formulations such as saturated pastes or other forms, may also be successfully used, particularly where visible appearance is not a limiting consideration (as in therapeutic applications).
- concentration of the polyamine anti-irritant compound(s) of the invention can readily be employed to optimize the concentration of the polyamine anti-irritant compound(s) of the invention and to ascertain if lower, or higher, concentrations are appropriate for a given formulation or irritation indication.
- concentration may be adjusted to account for the amount of formulation that is typically applied to a given skin area by the user, which will depend to an extent on the physical nature of the topical vehicle (e.g., lotion as compared to liquid spray vehicles).
- the amount of the compound required may be reduced in such cases where the formulation contains a skin penetration-enhancing ingredient or other agent which increases the ability of the compounds to permeate the stratum corneum to their site of anti-irritant activity.
- the formulations of the invention include an amount of polyamine anti-irritant compound (or compounds) capable of inhibiting irritation in susceptible individuals by at least about 20% or more, as measured by a mean reduction in cumulative imtation across a susceptible test population as exemplified in the clinical protocols described below.
- the formulations of the invention include an amount of anti-irritant compound capable of inhibiting irritation by at least about 40% or more in at least about 10% of the susceptible population, as measured by a reduction in cumulative irritation on an individual-by-individual basis (treated vs. control areas).
- This latter measure of efficacy reflects the fact that the present formulations, similar to many therapeutic products, may in some cases be effective in delivering a significant benefit to some, but not all, of the susceptible population.
- the optimum concentration of a compound of the invention may be reduced below (or within) the preferred ranges set forth above if some other anti-irritant component is included in the formulation along with the polyamine anti-irritant compound of the invention. In particular, it is contemplated that lower (e.g.
- halved amounts of the anti-irritant species may be used, while still maintaining comparable levels of anti-irritant activity, by further including an approximately equal concentration of, for example, a calcium-channel blocking or regulatory agent, or other anti-irritant agent such as a steroid or non-steroidal anti-inflammatory agent.
- a calcium-channel blocking or regulatory agent or other anti-irritant agent such as a steroid or non-steroidal anti-inflammatory agent.
- suitable additional anti-irritant ingredients are described in applicants' U.S. Patent Application Serial Nos.08/362,100, 08/362,101, 08/362,097, 08/362,055 and 08/362,058 (entitled “Formulations and Methods for Reducing Skin Irritation"), filed December 21, 1994 and incorporated by reference in their entirety.
- anti- irritant ingredients such as aloe vera, chamomile, ⁇ -bisabolol, Cola nitida extract, green tea extract, tea tree oil, licorice extract, allantoin, urea, caffeine or other xanthines, and glycyrrhizic acid and its derivatives, may also be beneficially incorporated into the formulations of the invention in order further to inhibit irritation effects or symptoms.
- the compounds of the invention are typically incorporated into the present formulations by mixing an appropriate amount of a sufficiently soluble form of the selected compound into the chosen formulation vehicle at an appropriate pH such that the polyamine is multiply protonated (e.g., where the side chains of the amino acid compounds are positively charged), along with such other skin care components as are desired.
- the selected compound be sufficiently soluble in the formulation vehicle as to allow a consistent formulation having the desired physical and topical application characteristics. It is also highly preferred that the compound (or compounds) chosen be sufficiently aqueous-soluble such that, upon application to the skin, the component compounds are taken up into the water-containing milieu of the skin.
- the anti-irritants chosen should be topically acceptable and preferably will not themselves be irritating, toxic or otherwise deleterious to the user.
- Suitable topical vehicles for use with the formulations of the invention are well known in the cosmetic and pharmaceutical arts, and include such vehicles (or vehicle components) as water; organic solvents such as alcohols (particularly lower alcohols readily capable of evaporating from the skin such as ethanol), glycols (such as glycerin), aliphatic alcohols (such as lanolin); mixtures of water and organic solvents (such as water and alcohol), and mixtures of organic solvents such as alcohol and glycerin (optionally also with water); lipid-based materials such as fatty acids, acylglycerols (including oils, such as mineral oil, and fats of natural or synthetic origin), phosphoglycerides, sphingolipids and waxes; protein-based materials such as collagen and gelatin; silicone-based materials (both non-volatile and volatile) such as cyclomethicone, demethiconol and dimethicone copolyol (Dow Corning); hydrocarbon-based materials such as petrolatum and squalene
- the vehicle may further include components adapted to improve the stability or effectiveness of the applied formulation, such as preservatives, antioxidants, skin penetration enhancers, sustained release materials, and the like. Examples of such vehicles and vehicle components are well known in the art and are described in such reference works as
- a suitable vehicle will depend on the particular physical form and mode of delivery that the formulation is to achieve.
- suitable forms include liquids (including dissolved forms of the compounds of the invention, as well as suspensions, emulsions and the like); solids and semisolids such as gels, foams, pastes, creams, ointments, "sticks” (as in lipsticks or underarm deodorant sticks), powders and the like; formulations containing liposomes or other delivery vesicles; rectal or vaginal suppositories, creams, foams, gels, ointments, enemas, douches and other forms.
- Typical modes of delivery include application using the fingers; application using a physical applicator such as a cloth, tissue, swab, stick or brush (as achieved, for example, by soaking the applicator with the formulation just prior to application, or by applying or adhering a prepared applicator already containing the formulation ⁇ such as a treated or premoistened bandage, wipe, washcloth or stick ⁇ to the skin); spraying (including mist, aerosol or foam spraying such as nasal sprays); dropper application (as, for example, with ear or eye drops) sprinkling (as with a suitable powder form of the formulation); soaking; an injection (particularly intradermal or subcutaneous injection). Iontophoresis or othe electromagnetic-enhanced delivery systems may also be usefully employed, as for example to increase delivery to the dermis.
- a physical applicator such as a cloth, tissue, swab, stick or brush
- a prepared applicator already containing the formulation ⁇ such as a
- the formulations of the invention are most preferably prepared such that the formulation (as occurring with any accompanying components) is substantially invisible upon application to the skin. This is particularly true in the case of many cosmetic formulations that are applied to the face or other exposed parts of the body, although it is also generally desirable that the formulation not be visible even if applied to non-exposed portions of the body. It will be recognized that in some cases, particularly with colored facial skin care products such as blushes, blemish covers, lipsticks and the like, the formulation will be designed to be visible on the skin; in such cases, it is desirable that the polyamine anti-irritant component itself be "invisible,” that is, that it not adversely change the appearance of the overall formulation as applied to the skin.
- the present anti-irritant species can be formulated in a form for topical oral administration to treat pain or irritation in the mouth, throat or other portions of the upper gastrointestinal tract such as that due to sore throats, canker sores, gum irritation or inflammation or the like, including such irritation as may be exacerbated by spicy or acidic foods as, for example, in the case of ulcers or heartburn.
- suitable forms for such oral administration include liquids (e.g. mouthwash or gargle solutions), lozenges, tablets, pills and capsules.
- the components used in such oral formulations should be chosen to be non-toxic. Methods for preparing oral formulations suitable for use in the present invention are well known in the art.
- formulations suitable for rectal, vaginal, nasal, pulmonary, respiratory, laryngopharyngeal, otic and ocular uses are contemplated and may be readily prepared.
- the objective of the clinical trials was to determine whether and to what extent the compounds of the present invention reduced or prevented skin irritation caused by lactic acid, an ⁇ -hydroxy carboxylic acid known for its skin irritating potential.
- the trials were conducted in a double blind, randomized, vehicle- controlled manner.
- Various formulations of the invention were tested in over 250 people.
- the subjects were women who had been screened and shown to exhibit normal to above normal susceptibility to irritation by the tested irritant. Tests were conducted in multiple panels of from 7 to 12 subjects each. Subjects were instructed not to wear any makeup or facial lotions to the clinic the day of testing. The subjects were instructed to wash their face with Ivory bar soap in the clinic prior to application of test solutions. Lactic acid skin-irritant compositions were formulated in an appropriate vehicle prior to application to the skin of the subjects. In the majority of the tests, the irritant composition was 7.5% lactic acid dissolved in a 10% ethanol-in- water solution. Other skin tests, such as those using capsaicin or benzoyl peroxide, are also suitable for evaluating the anti-irritant activity of the compounds.
- Test anti-irritant formulations were prepared by combining measured amounts of polyamine anti-irritants (Sigma or Aldrich) of the present invention (concentration 250 mM) in the lactic acid irritant composition.
- the test formulation was applied to a defined portion of the subject's skin, typically the face. Controls were performed by applying a corresponding formulation without any added polyamine anti-irritant to a contralateral portion of the subject's skin.
- test solutions were applied in a double blind, randomized fashion using the prepared solutions as previously placed in coded vials designated for use on either the right or left side of the face (or other test area). Solutions were typically applied using a cotton swab (six strokes) or sponge applicator to the face and cheek area extending from the midline of the nose over to the center of the cheek and from the cheek bone down to the jaw line. Application was made first to the right side and then to the left.
- Symptom scores were cumulated, separately for the anti-irritant-treated and control-treated areas, for each individual and also for the panel as a whole. Individuals not reporting a cumulative score of at least "7" on at least one treatment area were excluded (in a blinded fashion) from further analysis in order to ascertain anti-irritant efficacy with respect to the more severely-susceptible test subjects. From a practical standpoint, scores of "0" and "1" on the above scale would be considered highly desirable for a commercial product because such a response would likely not result in a consumer ceasing to use a product.
- Tables 1 and 2 A representative set of test results, performed using acid anti-irritant concentrations of 250 mM, is set forth in Tables 1 and 2 below.
- Table 1 reports representative test results using various straight-chain, branched-chain and heterocyclic polyamines.
- Table 2 lists representative test results for amino acid compounds of the lysine, arginine, histidine and ornithine families, including various derivatized amino acids. Where multiple panels were studied (n > 1), the percent inhibition is reported as the average of observed values and represents the cumulative irritation inhibition value.
- FIGURES 1 through 8 show more detailed experimental data for two panel tests conducted using L-arginine (FIGS. 1-4) and L-lysine (FIGS. 5-8) (250 mM each) as anti-irritant components of the subject formulations.
- FIGS. 1 and 5 show the time course of irritation responses for both anti-irritant-treated and non-treated (control) skin portions for the panels.
- FIGS. 2 and 6 show the cumulative irritation over time for the same panels, while FIGS. 3-4 and 7-8 show cumulative irritation suppression and treated/untreated irritation responses on a subject-by-subject basis. While individual responses vary somewhat, the overall efficacy of the subject formulations is evident.
- the anti-irritant compounds of the invention are preferably chosen from compounds that are not themselves irritating to the user.
- Ethylenediamine a small straight-chain polyamine, is an example of a compound reported to have irritant properties (Merck Index, Eleventh edition).
- Preliminary clinical tests of ethylenediamine using the protocol described above yielded variable results and suggested that the compound has relatively low anti-irritant properties ( ⁇ 20% inhibition) for some subjects and in fact may increase irritation somewhat (less than 20%) in some users.
Abstract
La présente invention concerne des compositions et formulations contenant des polyamines organiques à protons multiples (tels que des acides aminés dont les groupes latéraux portent des groupes amines). L'invention concerne également des procédés pour l'utilisation de ces formulations. Ces formulations et procédés permettent d'inhiber l'irritation cutanée chez les animaux.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48611/96A AU4861196A (en) | 1995-02-03 | 1996-02-02 | Formulations and methods for reducing skin irritation |
MX9705954A MX9705954A (es) | 1995-02-03 | 1996-02-02 | Formulaciones y metodos para reducir irritacion de la piel. |
JP8523692A JPH10513452A (ja) | 1995-02-03 | 1996-02-02 | 皮膚刺激を軽減するための製剤及び方法 |
EP96904530A EP0806947A4 (fr) | 1995-02-03 | 1996-02-02 | Formulations et procedes permettant de reduire l'irritation cutanee |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38426395A | 1995-02-03 | 1995-02-03 | |
US08/384,263 | 1995-02-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996023490A1 WO1996023490A1 (fr) | 1996-08-08 |
WO1996023490A9 true WO1996023490A9 (fr) | 1996-12-27 |
Family
ID=23516632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/001289 WO1996023490A1 (fr) | 1995-02-03 | 1996-02-02 | Formulations et procedes permettant de reduire l'irritation cutanee |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0806947A4 (fr) |
JP (1) | JPH10513452A (fr) |
AU (1) | AU4861196A (fr) |
CA (1) | CA2212127A1 (fr) |
MX (1) | MX9705954A (fr) |
WO (1) | WO1996023490A1 (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
EP0884046A1 (fr) * | 1997-05-30 | 1998-12-16 | Sara Lee/DE N.V. | Composition cosmétique à propriétés photoprotectrices |
TWI234467B (en) * | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
DE19757826A1 (de) * | 1997-12-24 | 1999-07-01 | Beiersdorf Ag | Neue Verwendung von chaotropen Verbindungen und chaotrope Verbindungen enthaltende Zubereitungen |
US6060471A (en) * | 1998-01-21 | 2000-05-09 | Styczynski; Peter | Reduction of hair growth |
US20040067212A1 (en) | 1998-03-11 | 2004-04-08 | Kabushiki Kaisha Soken | Skin conditioner |
JP2002510618A (ja) * | 1998-04-03 | 2002-04-09 | イレンチャック,セオドア,トニー | 皮膚科症状の治療へのポリアミンの使用 |
FR2783423B1 (fr) * | 1998-09-23 | 2002-06-14 | Oreal | Systeme de delivrance d'actif comprenant, sur une structure en film, une composition a base d'un derive d'acide salicylique, et ses utilisations |
US6444647B1 (en) | 1999-04-19 | 2002-09-03 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
MXPA01010631A (es) * | 1999-04-19 | 2002-03-14 | Procter & Gamble | Composiciones para el cuidado de la piel que contienen una combinacion de ingredientes activos para el cuidado de la piel. |
AU4361600A (en) * | 1999-04-19 | 2000-11-02 | Procter & Gamble Company, The | Skin care compositions containing combination of skin care actives |
US6492326B1 (en) * | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
FR2807645B1 (fr) * | 2000-04-12 | 2005-06-03 | Oreal | Utilisation d'inhibiteurs de l'alcool deshydrogenase dans le traitement cosmetique des matieres keratiniques |
FR2816837A1 (fr) * | 2000-11-17 | 2002-05-24 | Oreal | Utilisation d'au moins un derive amino sulfonique dans une composition destinee a favoriser la desquamation de la peau |
DE10106852A1 (de) | 2001-02-14 | 2002-09-05 | T Luger | Entzündungshemmende Verbindungen |
EP1407785A4 (fr) | 2001-06-14 | 2009-12-02 | Otsuka Pharma Co Ltd | Compositions medicinales |
WO2003013245A1 (fr) | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines et analogues assurant une protection des cellules a l'occasion des chimiotherapies et radiotherapies anticancereuses |
ITMI20020189A1 (it) * | 2002-02-01 | 2003-08-01 | Giuliani Spa | Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli |
US20040161392A1 (en) * | 2003-02-19 | 2004-08-19 | L'oreal S.A. | Skin peeling composition and method |
WO2004073701A1 (fr) * | 2003-02-19 | 2004-09-02 | Kuniyasu Soda | Inhibiteurs de lfa-1 et leur utilisation |
ITMI20031570A1 (it) * | 2003-07-31 | 2005-02-01 | Giuliani Spa | Composizione per uso dietetico, farmaceutico o cosmetico |
FR2860716B1 (fr) * | 2003-10-13 | 2005-12-09 | Oreal | Composition cosmetique comprenant un hydroxyacide, un polyholoside et un compose amino-sulfonique |
DE102004028599A1 (de) * | 2004-06-12 | 2005-12-29 | Henkel Kgaa | Milde Bleichmittel mit erhöhter Aufhellleistung |
NO20044818D0 (no) * | 2004-11-05 | 2004-11-05 | Bioforsk As | Spermin i kosmetiske preparater |
ITUD20050211A1 (it) | 2005-12-13 | 2007-06-14 | Rossana Castellana | Prodotto per il trattamento della pelle relativo procedimento di preparazione |
DE102006003926A1 (de) * | 2006-01-26 | 2007-08-02 | Henkel Kgaa | Aufhell- und/oder Färbemittel mit reduziertem Irritationspotential |
DE102006003924A1 (de) * | 2006-01-26 | 2007-08-02 | Henkel Kgaa | Aufhell- und/oder Färbemittel mit reduziertem Irritationspotential |
DE102006003927A1 (de) * | 2006-01-26 | 2007-08-02 | Henkel Kgaa | Aufhell- und/oder Färbemittel mit reduziertem Irritationspotential |
DE102006017901A1 (de) * | 2006-04-13 | 2007-10-25 | Henkel Kgaa | Aufhell- und/oder Färbemittel mit verbesserter Hautverträglichkeit |
JP2008156330A (ja) * | 2006-04-26 | 2008-07-10 | Toyobo Co Ltd | 賦活化剤及び抗老化剤 |
DE102006020789A1 (de) * | 2006-05-03 | 2007-11-08 | Henkel Kgaa | Aufhell- und/oder Färbemittel mit Imidazolen und Aminoalkoholen |
DE102006035252A1 (de) * | 2006-07-26 | 2008-01-31 | Henkel Kgaa | Haarfärbemittel mit Shea Butter |
WO2008051080A1 (fr) * | 2006-10-25 | 2008-05-02 | Fridtjof Bjerke | Crème pour l'épiderme comprenant une combinaison d'aloès officinal et de spermine |
WO2008091161A1 (fr) * | 2007-01-26 | 2008-07-31 | Fridtjof Bjerke | Composition cosmétique contenant de la spermine et de l'huile d'émeu |
EP2219594A4 (fr) * | 2007-11-27 | 2015-01-14 | Univ Manitoba | Utilisation d'un inhibiteur de transglutaminase pour le traitement de la peau |
US10221124B2 (en) * | 2015-03-17 | 2019-03-05 | Dsm Ip Assets B.V. | Process for the preparation of diaminobutane |
JP5966231B1 (ja) * | 2015-12-14 | 2016-08-10 | 有限会社アント | アミノ酸配合顔用皮膚外用剤 |
US20210212964A1 (en) * | 2018-06-08 | 2021-07-15 | Vivier Canada Inc. | Sterile topical saline putrescine formulation and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3861868A (en) * | 1971-03-30 | 1975-01-21 | Procter & Gamble | Dyeing human hair with oxidation dyes and arginine or a protamine protein |
US4076799A (en) * | 1972-12-27 | 1978-02-28 | Cincinnati Milacron, Inc. | Method of inhibiting skin irritation |
JPS6025479B2 (ja) * | 1977-03-31 | 1985-06-18 | 三洋化成工業株式会社 | 香粧品・洗浄剤用界面活性剤組成物 |
JPS54163819A (en) * | 1978-06-14 | 1979-12-26 | Meito Sangyo Kk | Digestive tract ulcer and injury treating agent |
US4507321A (en) * | 1982-02-17 | 1985-03-26 | The Research Foundation Of State University Of New York | Epithelial cell growth regulating composition containing polyamines and a method of using same |
EP0100827B1 (fr) * | 1982-08-17 | 1986-09-03 | Rosical Limited | Composition pharmaceutique contenant un acide aminosulfonique aliphatique |
US4704234A (en) * | 1983-01-17 | 1987-11-03 | American Cyanamid Company | Compositions comprising imidazole, pyrazole or derivatives thereof for removing undesirable organic matter from a surface |
IT1190348B (it) * | 1986-06-16 | 1988-02-16 | Lisapharma Spa | Impiego topico vaginale del p-isobutilfenilpropionato di lisina nel trattamento antiinfiammatorio |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US5252322A (en) * | 1989-09-22 | 1993-10-12 | The Gillette Company | Skin tanning compositions containing imidazoles |
AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
JP3575084B2 (ja) * | 1994-11-29 | 2004-10-06 | 味の素株式会社 | 殺菌消毒剤配合組成物 |
-
1996
- 1996-02-02 EP EP96904530A patent/EP0806947A4/fr not_active Withdrawn
- 1996-02-02 WO PCT/US1996/001289 patent/WO1996023490A1/fr not_active Application Discontinuation
- 1996-02-02 JP JP8523692A patent/JPH10513452A/ja active Pending
- 1996-02-02 CA CA002212127A patent/CA2212127A1/fr not_active Abandoned
- 1996-02-02 AU AU48611/96A patent/AU4861196A/en not_active Abandoned
- 1996-02-02 MX MX9705954A patent/MX9705954A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996023490A9 (fr) | Formulations et procedes permettant de reduire l'irritation cutanee | |
EP0801554B1 (fr) | Formulations et procedes pour diminuer l'irritation de la peau | |
WO1996023490A1 (fr) | Formulations et procedes permettant de reduire l'irritation cutanee | |
US5756107A (en) | Formulations and methods for reducing skin irritation | |
EP0806933B1 (fr) | Formulations et procedes pour diminuer l'irritation de la peau | |
US5958436A (en) | Formulations and methods for reducing skin irritation | |
US6139850A (en) | Formulations and methods for reducing skin irritation | |
WO1996019183A9 (fr) | Formulations et procedes pour diminuer l'irritation de la peau | |
MXPA97005954A (en) | Formulations and methods to reduce irritation of the p | |
AU4606496A (en) | Formulations and methods for reducing skin irritation | |
US20010014342A1 (en) | Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained | |
MXPA97004778A (en) | Formulations to reduce skin irritations and use of mis | |
EP0801570B1 (fr) | Formulations et procedes pour diminuer l'irritation de la peau | |
WO1996019228A9 (fr) | Formulations et procedes pour diminuer l'irritation de la peau | |
AU1487500A (en) | Formulations and methods for reducing skin irritation | |
AU1362800A (en) | Formulations and methods for reducing skin irritation |